U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
Nivolumab (Opdivo): CADTH Reimbursement Recommendation: Indication: In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with human epidermal growth factor receptor 2–negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma [Internet].

Nivolumab (Opdivo): CADTH Reimbursement Recommendation: Indication: In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with human epidermal growth factor receptor 2–negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Mar.

Table of contents


Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...